Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial
AME Clinical Trials Review · 2026-04 · 4 · 15-15
DOI: 10.21037/actr-25-72 ↗Kurz gefasst
Editorial in der Zeitschrift AME Clinical Trials Review, 2026-04. Verfasst von Daniel K Reef und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, UNC (University of North Carolina) Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology, UNC (University of North Carolina) Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
ORCID-Profile: Daniel K Reef, Natalie Grover
Förderung
- NCI NIH HHS
Zitieren
APA
Reef, D. K., & Grover, N. (2026). Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial. AME Clinical Trials Review, 4, 15-15. https://doi.org/10.21037/actr-25-72
Vancouver
Reef DK, Grover N. Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial. AME Clinical Trials Review. 2026;4:15-15. doi:10.21037/actr-25-72
BibTeX
@article{Reef2026,
author = {Reef, Daniel K and Grover, Natalie},
title = {Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial},
journal = {AME Clinical Trials Review},
year = {2026},
volume = {4},
pages = {15--15},
doi = {10.21037/actr-25-72}
}
EUVIMED